Form 4: Edgewise Therapeutics Executive Behrad Derakhshan Reports Stock Option and RSU Grant
SEC Form 4
Behrad Derakhshan, Chief Business Officer of Edgewise Therapeutics, reports the acquisition of stock options and restricted stock units (RSUs) on August 12, 2024.
Summary
- Behrad Derakhshan, the Chief Business Officer of Edgewise Therapeutics, Inc., filed a Form 4 on August 14, 2024.
- The report details the grant of stock options and restricted stock units (RSUs) to Derakhshan on August 12, 2024.
- Derakhshan received options to purchase 138,750 shares of common stock at an exercise price of $17.05.
- These options vest monthly over four years, starting August 12, 2024.
- Additionally, Derakhshan was granted 23,125 RSUs, which vest in four equal annual installments beginning August 12, 2024.
- Each RSU represents a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon vesting.
Sentiment
Score: 7
Explanation: The document reflects a standard executive compensation practice, indicating a stable and ongoing operation. The sentiment is neutral to slightly positive as it suggests continued investment in key personnel.
Positives
- The grant of stock options and RSUs aligns the executive's interests with those of the shareholders.
- The vesting schedules incentivize continued service and contribution to the company's success.
Future Outlook
The document does not contain specific forward-looking statements beyond the vesting schedules of the granted securities.
Industry Context
Stock option and RSU grants are common compensation practices for executives in publicly traded companies, particularly in the biotechnology sector, to incentivize performance and align interests with shareholders.
Comparison to Industry Standards
- Executive compensation packages, including stock options and RSUs, are standard practice in the pharmaceutical and biotechnology industries.
- Companies like Amgen, Biogen, and Vertex Pharmaceuticals also utilize similar equity-based compensation to attract and retain key personnel.
- The vesting schedules (monthly for options, annual for RSUs) are typical for these types of grants.
Stakeholder Impact
- Shareholders may view the equity grants as a positive sign, aligning management's interests with the company's long-term success.
- Employees may see this as a positive indicator of the company's commitment to its leadership team.
Key Dates
| Date | Description |
|---|---|
| 08/12/2024 | Date of the transaction (grant of stock options and RSUs) |
| 08/12/2024 | Start date for monthly vesting of stock options |
| 08/12/2024 | Start date for annual vesting of RSUs |
| 08/12/2034 | Expiration date of stock options |
| 08/14/2024 | Date the Form 4 was filed |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.